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Abstract
Background: Malignant brain cancer persists as a major disease of morbidity and mortality in adults and is the second
leading cause of cancer death in children. Many current therapies for malignant brain tumors fail to provide long-term
management because they ineffectively target tumor cells while negatively impacting the health and vitality of normal brain
cells. In contrast to brain tumor cells, which lack metabolic flexibility and are largely dependent on glucose for growth
and survival, normal brain cells can metabolize both glucose and ketone bodies for energy. This study evaluated the
efficacy of KetoCal®, a new nutritionally balanced high fat/low carbohydrate ketogenic diet for children with epilepsy, on
the growth and vascularity of a malignant mouse astrocytoma (CT-2A) and a human malignant glioma (U87-MG).
Methods: Adult mice were implanted orthotopically with the malignant brain tumors and KetoCal® was administered
to the mice in either unrestricted amounts or in restricted amounts to reduce total caloric intake according to the
manufacturers recommendation for children with refractory epilepsy. The effects KetoCal®  on tumor growth,
vascularity, and mouse survival were compared with that of an unrestricted high carbohydrate standard diet.
Results: KetoCal® administered in restricted amounts significantly decreased the intracerebral growth of the CT-2A and
U87-MG tumors by about 65% and 35%, respectively, and significantly enhanced health and survival relative to that of the
control groups receiving the standard low fat/high carbohydrate diet. The restricted KetoCal® diet reduced plasma
glucose levels while elevating plasma ketone body (β-hydroxybutyrate) levels. Tumor microvessel density was less in the
calorically restricted KetoCal® groups than in the calorically unrestricted control groups. Moreover, gene expression for
the mitochondrial enzymes, β-hydroxybutyrate dehydrogenase and succinyl-CoA: 3-ketoacid CoA transferase, was
lower in the tumors than in the contralateral normal brain suggesting that these brain tumors have reduced ability to
metabolize ketone bodies for energy.
Conclusion: The results indicate that KetoCal® has anti-tumor and anti-angiogenic effects in experimental mouse and
human brain tumors when administered in restricted amounts. The therapeutic effect of KetoCal® for brain cancer
management was due largely to the reduction of total caloric content, which reduces circulating glucose required for
rapid tumor growth. A dependency on glucose for energy together with defects in ketone body metabolism largely
account for why the brain tumors grow minimally on either a ketogenic-restricted diet or on a standard-restricted diet.
Genes for ketone body metabolism should be useful for screening brain tumors that could be targeted with calorically
restricted high fat/low carbohydrate ketogenic diets. This preclinical study indicates that restricted KetoCal® is a safe and
effective diet therapy and should be considered as an alternative therapeutic option for malignant brain cancer.
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Background
Malignant brain cancer persists as a major disease of mor-
bidity and mortality in adults and is the second leading
cause of cancer death in children [1-4]. Many current ther-
apies for malignant brain tumors are ineffective in provid-
ing long-term management because they focus on the
defects of the tumor cells at the expense of the health and
vitality of normal brain cells [5-7]. We previously showed
that caloric restriction (CR) is anti-angiogenic, anti-
inflammatory, and pro-apoptotic in the experimental
mouse (CT-2A astrocytoma) and the human (U87-MG
malignant glioma) brain tumors [8-11]. CR targets tumor
cells by reducing circulating glucose levels and glycolysis,
which tumor cells need for survival, and by elevating
ketone bodies, which provide normal brain cells with an
alternative fuel to glucose [5,9,11]. We previously used
linear regression analysis to show that blood glucose lev-
els could predict CT-2A growth as well as insulin-like
growth factor 1 (IGF-1) levels, which influences tumor
angiogenesis [8,9]. In contrast to glucose, ketone bodies
(β-hydroxybutyrate and acetoacetate) bypass glycolysis
and directly enter the mitochondria for oxidation [12,13].
By bypassing glycolysis, ketone bodies are also effective
for treatment of inherited defects in glucose transporters
and pyruvate dehydrogenase, which connects glycolysis
with respiration [14-16]. Ketone bodies are more energet-
ically efficient than either pyruvate or fatty acids because
they have a greater hydrogen/carbon ratio (more reduced)
than pyruvate and, unlike fatty acids, do not uncouple
mitochondria [5,17]. The transition from glucose to
ketone bodies for brain energy metabolism is best under
the natural conditions of CR [5,8,18].
The metabolism of β-hydroxybutyrate (β-OHB), the
major circulating ketone body, for energy depends on the
expression of two key mitochondrial enzymes: β-hydroxy-
butyrate dehydrogenase (β-OHBDH), and succinyl-CoA:
3-ketoacid CoA transferase (SCOT) [13,19-21]. These
enzymes become critical when neurons and glia transition
to ketone bodies in order to maintain energy balance
under conditions of reduced glucose availability. In addi-
tion to serving as a more efficient metabolic fuel than glu-
cose, ketone bodies also possess anti-inflammatory
potential through reduction of reactive oxygen species
and increase of glutathione peroxidase activity [5,17,22].
Brain tumors, like most malignant tumors, are largely
dependent on glucose and glycolysis for their growth and
survival due to abnormalities in the number and function
of their mitochondria [5,8,23-27]. The transition from
glucose to ketone bodies as the primary energy source of
the brain under calorically restricted conditions exploits
the metabolic deficiencies of brain tumor cells while
enhancing the health and vitality of normal neurons and
glia according to principles of evolutionary biology and
metabolic control theory [5,28].
Nebeling and co-workers previously found that a high fat/
low carbohydrate ketogenic diet (KD), consisting of
medium chain triglycerides, provided long-term manage-
ment of pediatric astrocytoma while enhancing the nutri-
tional status of the patients [29]. The findings in human
pediatric astrocytoma were confirmed in the experimental
mouse CT-2A astrocytoma using a lard-based rodent
ketogenic diet [8,9]. CR and some KDs, however, are not
standardized diets and may be difficult to implement in
the clinic due to issues of compliance. For example, CR in
mice mimics therapeutic fasting in humans, involving
water-only dieting, whereas medium chain triglyceride or
lard-based ketogenic diets can cause gastrointestinal and
kidney problems in both children and adults [30-33]. Our
goal was to develop a more effective alternative diet ther-
apy for brain cancer that could extend survival without
compromising the health and vitality of normal cells.
In this study we evaluated the therapeutic efficacy of Keto-
Cal®, a new nutritionally balanced soybean oil ketogenic
diet that was formulated specifically for managing refrac-
tory epilepsy in children [34]. No prior studies have eval-
uated the therapeutic efficacy of KetoCal® for brain cancer
management. Here we show that KetoCal®, given in calor-
ically restricted amounts significantly reduced circulating
plasma glucose levels while significantly elevating ketone
body levels in mice bearing orthotopic CT-2A and U87-
MG brain tumors. Moreover, the restricted KetoCal® diet
reduced brain tumor growth and microvessel density,
while extending mouse survival. Gene expression for β-
OHBDH and SCOT was lower in the tumors than in con-
tralateral normal brain suggesting that the brain tumors
have reduced ability to metabolize ketone bodies for
energy. This preclinical study indicates that KetoCal® is a
safe and effective diet therapy for malignant brain cancer
and can be considered as an alternative or adjuvant thera-




Mice of the C57BL/6J (B6) strain and the BALBc/J-severe
combined immunodeficiency (SCID) strain were
obtained from the Jackson Laboratory, Bar Harbor, ME.
The mice were propagated in the animal care facility of the
Department of Biology, Boston College, using animal
husbandry conditions described previously [36]. Male
mice (10–12 weeks of age) were used for the studies and
were provided with food under either restricted or unre-
stricted conditions (as below). Water was provided ad libi-
tum  to all mice. The SCID mice were maintained in
laminar flow hoods in a pathogen free environment. All
animal experiments were carried out with ethical commit-
tee approval in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory AnimalsNutrition & Metabolism 2007, 4:5 http://www.nutritionandmetabolism.com/content/4/1/5
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and were approved by the Institutional Animal Care Com-
mittee.
Brain tumor models
The syngeneic mouse brain tumor CT-2A, was originally
produced by implantation of a chemical carcinogen, 20-
methylcholanthrene, into the cerebral cortex of B6 mice
and was characterized as an anaplastic astrocytoma
[37,38]. The morphological, biochemical, and growth
characteristics of the CT-2A mouse brain tumor were pre-
viously described [37,39-42]. The U87-MG (U87) tumor
was originally derived from a human malignant glioma
cell line and was grown as a xenograft in the SCID mice
[43,44].
Intracerebral and subcutaneous tumor implantation
The mouse CT-2A and human U87 tumors were
implanted into the cerebral cortex of the B6 or SCID mice,
respectively, using a trocar as we previously described
[41]. Briefly, mice were anesthetized with 2,2,2-tribro-
moethanol (Sigma Aldrich, St. Louis, MO) given intra-
peritoneally and their heads were shaved and swabbed
with 70% ethyl alcohol under sterile conditions. Small
tumor pieces (about 1 mm3) from donor mice were
implanted into the right cerebral hemisphere of anesthe-
tized recipient mice as we recently described [41]. Initia-
tion of tumors from intact tumor pieces is preferable to
initiation from cultured cells, since the tumor tissue con-
tains an already established microenvironment that facil-
itates rapid tumor growth [41]. All of the mice recovered
from the surgical procedure and were returned to their
cages when they appeared fully active.
For the survival studies, CT-2A or U87 flank-grown
tumors were removed from B6 or SCID mice, respectively,
and were rinsed and diced in cold phosphate-buffered
saline (PBS) at pH 7.4. Mice were anesthetized with isoflu-
rane (Halocarbon, NJ) and 0.1 ml of diced tumor tissue,
suspended in 0.2 ml PBS, was implanted subcutaneously
(s.c.) in the right flank by injection using a 1 cc tuberculin
syringe and 18-gauge needle. The flanks of recipient mice
were shaved in order to facilitate tumor detection and
growth assessment. The inoculated mice were monitored
daily for nodule formation.
Diets and feeding
The mice were group housed prior to the initiation of the
experiment and were then individually housed in plastic
shoebox cages one day before tumor implantation. All
mice received PROLAB chow (Agway Inc., NY) prior to the
experiment. This is a standard high carbohydrate mouse
chow diet (SD) and contains a balance of mouse nutri-
tional ingredients. According to the manufacturers speci-
fication, this diet delivers 4.4 Kcal/g gross energy, where
fat, carbohydrate, protein, and fiber comprised 55 g, 520
g, 225 g, and 45 g/Kg of the diet, respectively. The Keto-
Cal® ketogenic diet was obtained as a gift from Nutricia
North America (Rockville, MD, formally SHS Interna-
tional, Inc.). KetoCal®  is a nutritionally complete
ketogenic formula and, according to the manufacturers
specification, delivers 7.2 Kcal/g gross energy where fat,
carbohydrate, protein, and fiber comprised 720 g, 30 g,
150 g, and 0 g/Kg of the diet, respectively. There are also
minor differences between the two diets for the content
(g/kg of diet) of amino acids, vitamins, minerals and trace
elements. The diet has a ketogenic ratio (fats: proteins +
carbohydrates) of 4:1 and the fat was derived from soy-
bean-oil. The KetoCal® diet was fed to the mice in paste
form (water: KetoCal®; 1:2) within the cage using proce-
dures as we previously described [18]. A comparison of
the nutritional composition of the SD and the KetoCal®
diet is presented in Table 1.
The animal room was maintained at 22 ± 1°C, and cotton
nesting pads were provided for additional warmth. All
intracerebral (i.c.) tumor-bearing B6 and SCID mice were
maintained on the SD for three days following tumor
implantation (day 0, Figure 1) and were then randomly
assigned (arrow, Figure 1) to one of three diet groups that
received either: 1) the standard diet fed ad libitum, or unre-
stricted (SD-UR), 2) the KetoCal® diet fed ad libitum, or
unrestricted (KC-UR), 3) the KC diet restricted to reduce
body weight by approximately 20% of the original body
weight at day 3 (KC-R). The dietary treatments were con-
tinued for 8 days for tumor weight analysis. For the sur-
vival analysis, the dietary treatment was initiated 7 days
after subcutaneous implantation and continued until the
tumors reached 2.5 cm3.
Table 1: Composition (%) of the Standard Diet and the KetoCal® Ketogenic dieta




Energy (Kcal/gr) 4.4 7.2
a Values obtained from normalizing energy content (see Methods)Nutrition & Metabolism 2007, 4:5 http://www.nutritionandmetabolism.com/content/4/1/5
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Influence of diet on body weight in B6 mice bearing the mouse CT-2A astrocytoma (A), and in SCID mice bearing the human  U87 glioma (B) Figure 1
Influence of diet on body weight in B6 mice bearing the mouse CT-2A astrocytoma (A), and in SCID mice bearing the human 
U87 glioma (B). Tumors were implanted orthotopically at day 0, and diets were initiated at day 3 (arrow). The SD-UR, KC-UR, 
and KC-R represent the standard high carbohydrate diet fed unrestricted, the KetoCal® diet fed unrestricted, and the Keto-
Cal® diet fed in restricted amounts, respectively. Values are expressed as the mean ± SEM (n = 12–14 mice per group), and 
asterisks indicate that the body weights of the KC-R mice (▲) were significantly lower than those of the unrestricted control 
groups at P < 0.01.Nutrition & Metabolism 2007, 4:5 http://www.nutritionandmetabolism.com/content/4/1/5
Page 5 of 15
(page number not for citation purposes)
Tumor growth and survival analysis
Intracerebral tumor growth was analyzed directly by
measuring total tumor wet weight. Tumors were dissected
from normal appearing brain tissue and were weighed.
Survival was determined as the time for subcutaneous
tumors to reach the size of 2.5 cm3 after tumor inocula-
tion as previously described [45]. Calipers were used to
measure tumor volume as previously described [46].
Tumor nodules appeared approximately 7 days following
inoculation.
Measurement of plasma glucose and β-hydroxybutyrate 
(β-OHB)
Blood was collected from mice on the last day of the
experiment (between 1–4 pm) and before sacrifice and
tumor resection. All mice were fasted for 2 hours before
blood collection to stabilize blood glucose levels. The
mice were anesthetized with isoflurane (Halocarbon, NJ),
and the blood was collected from the heart into
heparinized tubes. The blood was centrifuged at 1,500 × g
for 10 min, and the plasma was collected and stored at -
80°C until assayed. Plasma glucose and β-OHB concen-
trations were measured spectrophotometrically using the
StanBio® Enzymatic Glucose Assay (1075-102) (StanBio
Laboratory, Boerne, TX, USA) and a modification of the
Williamson et al., enzymatic procedure [47], respectively.
For blood ketone body analysis, we measured only β-
OHB levels because this is the major blood ketone body
in plasma [48,49].
Histology
Tumor samples were fixed in 10% neutral buffered forma-
lin (Sigma, St. Louis, MO) and embedded in paraffin.
Tumors were sectioned and examined by light micros-
copy. For the histological studies, treatment was initiated
as described above and was continued for 7 days to pre-
vent tumor-associated tissue distortion.
Factor VIII Staining and Microvessel Analysis
Tumor sections were incubated with trypsin at 37°C for
30 min after deparaffinization, rehydration, and washing
as we described recently [10,11]. Briefly, the sections were
quenched with 0.3% H2O2-methanol for 30 min and then
blocked with 10% normal goat serum in phosphate buffer
plus albumin (PBA) that contained 100 ml of 0.01 M
phosphate and 0.9% sodium chloride (pH 7.4) with 1.0 g
of bovine serum albumin and 0.1 ml of Tween 20. The
sections were treated with rabbit polyclonal antibody
directed against human factor VIII-related antigen (Dako
Corp., Carpinteria, CA; 1:100 dilution with PBA) fol-
lowed by a biotinylated anti-rabbit IgG at 1:100 dilution
(Vector Laboratories, Inc., Burlingame, CA). The sections
were then treated with avidin-biotin complex followed by
3,3'-diaminobenzidine as substrate for staining according
to the manufacturers directions (Vectastain Elite ABC kit;
Vector Laboratories, Inc.). The sections were then rinsed
three times with 0.01 M phosphate buffer with 0.9%
NaCl. Sections were counterstained with methyl green
and mounted. Corresponding tissue sections without pri-
mary antibody served as negative controls. Microvessel
density was quantified by examining areas of vascular hot
spots in high power fields (hpf, 200 ×) as previously
described [50] with some modifications [51]. Briefly, sec-
tions were scanned at 40 × and at 100 × for the localiza-
tion of vascular hot spots. Blood vessels were counted at
200 × in the three most non-necrotic vascular areas of the
tumor. The values of the three sections were averaged for
each CT-2A tumor. Branching structures were counted as
a single vessel as described previously [50]. Blood vessels
were not counted in the U87 tumor due to extensive hot
spot areas. In this case, only the tumor sections were
shown for qualitative analysis.
Semi-quantitative RT-PCR
Total RNA was isolated from homogenized tissue using
TRIzol Reagent (Invitrogen, La Jolla, CA), following the
manufacturers protocol. Spectrophotometric measure-
ments at 260 and 280 nm determined RNA concentration
and purity. Single-strand cDNA was synthesized from
total RNA (3 μg) by using oligo (dT) primers (Promega,
Madison, WI) in a 20-μl reaction with Moloney murine
leukemia virus reverse transcriptase (M-MLV RT;
Promega) according to the manufacturers protocol. cDNA
(3 μl) was used for PCR amplification of specific regions
of the β-OHBDH, SCOT, and β-actin genes. Primer
sequences and amplicon information for the mouse and
the human β-actin, β-OHBDH, and SCOT genes can be
viewed at NCBI (National Center for Biotechnology Infor-
mation, PubMed) using the accession numbers
EF095208-EF095213. Gradient PCR was performed to
obtain optimal primer annealing temperatures as previ-
ously described [52]. In order to determine the optimal
linear range for semi-quantitative RT-PCR, PCR was per-
formed at increasing cycle numbers. PCR amplification
was performed with Taq DNA polymerase (Promega)
using similar protocols for each gene. PCR products (10
μl) were separated on 1.0 % agarose gels containing ethid-
ium bromide, visualized with UV light, and analyzed
using 1D Kodak Software (Eastman Kodak Co., Rochester,
NY).
Statistical analysis
The one-way analysis of variance (ANOVA) was used to
analyze body weight, tumor growth, plasma glucose, and
β-OHB levels [53]. The Fishers PLSD test was used to cal-
culate two-sided pair-wise comparison among different
test groups by use of Statview 5.0. In each figure, n desig-
nates the number of individual mice analyzed. Error bars
in the figures are expressed as mean ± SEM. Survival was
computed and plotted according to the nonparametricNutrition & Metabolism 2007, 4:5 http://www.nutritionandmetabolism.com/content/4/1/5
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Kaplan-Meier analysis, and comparison of control and
treated groups was made using the log-rank test [53].
Results
The objective of this study was to determine if the Keto-
Cal® ketogenic diet could be therapeutic against experi-
mental mouse and human brain tumors when
administered in restricted amounts according to recom-
mendations for treatment of children with refractory epi-
lepsy. In contrast to other ketogenic diet formulations
(lard-based or medium chain triglyceride diets), which are
not standardized or commercially available, KetoCal® is a
nutritionally complete medical food for children that
would be widely available for alternative indications such
as malignant brain cancer. Because we previously showed
that CR of the high carbohydrate standard diet has anti-
tumor and anti-angiogenic effects against the CT-2A and
U87 experimental brain tumors [10,11], we did not
include a hypocaloric group for the high carbohydrate
diet in this study. Consequently, the restricted KetoCal®
mouse groups were compared to mouse groups receiving
either the standard chow diet or the KetoCal® diet in unre-
stricted amounts.
Body weight and diet tolerance
Body weights remained similar in the unrestricted stand-
ard diet fed group (SD-UR) and in the unrestricted Keto-
Cal® diet fed group (KC-UR) throughout the study despite
major differences in the caloric content and composition
of the diets (Table 1 and Figure 1A and 1B). The restriction
of KetoCal® in the KC-R group was according to the man-
ufacturers recommendation for the management of child-
hood epilepsy (Nutricia North America). This involved
administration of 65–70% recommended daily allowance
of calories or an approximate 30–35% calorie restriction.
This degree of dietary restriction gradually produced an
approximate 20–23% body weight reduction by 11 days
post i.c. tumor implantation in the B6 and SCID KC-R
groups. No signs of vitamin or mineral deficiency were
observed in the KC-R mice based on standard criteria in
mice [54]. Indeed, physical activity and grooming behav-
ior was noticeably greater in the KC-R groups than in the
SD-UR and KC-UR groups. These findings indicate that
KetoCal®  was well tolerated in tumor-bearing B6 and
SCID mice and, when given in restricted amounts, pro-
duced noticeable improvement in health and vitality.
Influence of diet on tumor growth and mouse survival
Intracerebral growth of the CT-2A and U87 tumors was
rapid in both the SD-UR and KC-UR groups, but growth
was reduced by approximately 65% and 35% in the KC-R
groups, respectively (Figure 2A and 2B). These reductions
in tumor weight exceeded the reductions in body weight.
It is important to mention that all implanted CT-2A and
U87 tumors grew in the KC-R groups, indicating that
restricted feeding did not prevent tumor "take" but signif-
icantly reduced the intracerebral growth rate. Survival,
assessed as the time required for subcutaneous tumor
nodules to reach 2.5 cm3, was significantly longer in the
KC-R groups than in the SD-UR or KC-UR groups (Figure
3A and 3B). No significant differences in survival were
found among tumor-bearing mice in the SD-UR or the
KC-UR groups. These findings indicate that KetoCal®,
administered in recommended restricted amounts, signif-
icantly reduced tumor growth and extended survival in
mice bearing either the mouse CT-2A or human U87
brain tumors.
Influence of diet on plasma glucose and β-OHB levels
A transition from glucose to ketone bodies for energy
under caloricaly restricted conditions is known to inhibit
brain tumor growth through multiple integrated systems
[5,9-11]. Plasma glucose levels were significantly lower in
the KC-R mouse groups than in the SD-UR or the KC-UR
groups (Figure 4A and 4B). Plasma glucose levels, how-
ever, were similarly high in both UR-fed mouse groups.
These findings are consistent with our previous studies in
mice showing that the KD does not lower plasma glucose
levels when administered in unrestricted amounts [8,18].
In contrast to glucose levels, circulating β-OHB levels were
2 to 3-fold greater in the KC-UR groups than in the SD-UR
groups (Figure 4C and 4D). Interestingly, β-OHB levels
were 5 to 9-fold greater in the KC-R groups than in the SD-
UR groups. These findings are also consistent with our
previous studies in mice showing that circulating β-OHB
levels are greater under restricted than unrestricted dietary
conditions [8,18,55,56].
Influence of diet on brain tumor vascularity
To determine if KetoCal®  influenced angiogenesis, we
used Factor VIII immunostaining to examine blood vessel
densities in the CT-2A and U87 brain tumors. Three inde-
pendent CT-2A and U87 tumors were chosen at random
from each dietary group. The number of blood vessels in
the CT-2A tumor was noticeably less in the KC-R group
than in the SD-UR group (Figure 5A). Also, CT-2A micro-
vessel density/high power field was significantly less in
the KC-R group than in the SD-UR group (Figure 5B). As
found in the CT-2A tumor, the number of blood vessels in
the U87 tumor was noticeably less in the KC-R group than
in the SD-UR group (Figure 5C). Due to the high density
of blood vessels in the U87 tumor compared to the CT-2A
tumor, it was not possible to accurately measure micro-
vessel density/hpf in the U87 tumor. No differences in the
number or density of blood vessels were observed
between the SD-UR and KC-UR groups for either tumor
(data not shown). These findings indicate that KetoCal®,
administered in restricted amounts, was anti-angiogenic
in the CT-2A and U87 brain tumors.Nutrition & Metabolism 2007, 4:5 http://www.nutritionandmetabolism.com/content/4/1/5
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Differential mRNA expression for β-hydroxybutyrate 
dehydrogenase (β-OHBDH) and succinyl-CoA: 3-ketoacid 
CoA transferase (SCOT) in normal brain and in brain 
tumor tissue
β-OHBDH and SCOT are required for the metabolism of
ketone bodies for energy in brain mitochondria
[13,20,21]. We used semi-quantitative RT-PCR to com-
pare β-OHBDH and SCOT mRNA levels in the CT-2A and
U87 tumor tissue grown in the right cerebral hemisphere
with those levels in the normal appearing brain tissue of
the contralateral left hemisphere (Figure 6A and 6B). β-
OHBDH and SCOT mRNA levels were significantly lower
in the CT-2A and the U87 tumor tissue than in the normal
appearing contralateral brain tissue. No differences in β-
OHBDH and SCOT mRNA levels were found between
normal appearing brain tissue from tumor-bearing mice
and brain tissue from non-tumor-bearing mice (data not
shown). These findings suggest that the CT-2A and the
U87 tumor cells are less capable than the normal mouse
brain cells in using ketone bodies for energy.
Discussion
We found that KetoCal®, a nutritionally balanced and
commercially available ketogenic diet for children with
epilepsy, significantly reduced the orthotopic growth and
the vascularity of the mouse astrocytoma (CT-2A) and the
human glioma (U87). Moreover, KetoCal® significantly
prolonged survival in the tumor-bearing mice. It is impor-
tant to mention that the anti-angiogenic and growth
inhibitory effects of KetoCal® were observed only when
the diet was administered in restricted amounts but were
not seen when the diet was administered ad libitum, or in
unrestricted amounts. These findings support previous
observations that restriction of dietary calories has power-
ful anti-angiogenic and anti-inflammatory effects against
cancer, including brain cancer [9-11,51,57,58]. Reduced
caloric content lowers circulating glucose levels as we
found in this study and in our previous studies [10,11].
Indeed, tumor growth is more strongly correlated with cir-
culating glucose levels than with circulating ketone body
levels [8]. The reduction in glucose levels following
restriction of dietary calories largely accounts for why
tumors grow minimally on either restricted ketogenic
diets or on restricted high carbohydrate standard diets.
Restriction of calories in humans may be difficult to
achieve, however, due to issues of compliance. Compli-
ance may be better with KetoCal® as this diet was designed
for managing refractory human epilepsy under calorically
restricted conditions. CR, however, is not directly compa-
rable in mice and humans. For example, a 40% CR diet in
mice is comparable to therapeutic fasting in humans,
which can be difficult for many people [30]. In addition
to reducing circulating glucose levels, a restriction of total
calories also reduces potential adverse effects of the high
fat content of the diet since energy homeostasis is maxi-
mized under CR regardless of caloric origin [8,30]. The
restricted KetoCal®  diet should therefore be easier to
implement than therapeutic fasting for brain cancer
patients.
Although we previously showed that CR of a high carbo-
hydrate standard diet or of a rodent ketogenic diet simi-
larly reduce blood glucose levels, which tumor cells
depend upon for survival [10,11], our findings in this
Influence of diet on the intracerebral growth of the CT-2A (A) and the U87 (B) brain tumors Figure 2
Influence of diet on the intracerebral growth of the CT-2A (A) and the U87 (B) brain tumors. The asterisks indicate that the 
tumor weights of the KC-R groups differed from those of the SD-UR groups at the P < 0.03 *, and the P < 0.01 ** level. Other 
conditions are the same as shown in Figure 1.Nutrition & Metabolism 2007, 4:5 http://www.nutritionandmetabolism.com/content/4/1/5
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Influence of diet on the percentage of mice with the CT-2A (A) or the U87 (B) brain tumors < 2.5 cm3 in size Figure 3
Influence of diet on the percentage of mice with the CT-2A (A) or the U87 (B) brain tumors < 2.5 cm3 in size. Data are 
expressed as Kaplan-Meier survival curves. Survival was significantly longer in the mice on KC-R diet (▲) than on either the 
SD-UR or KC-UR diets P < 0.01.Nutrition & Metabolism 2007, 4:5 http://www.nutritionandmetabolism.com/content/4/1/5
Page 9 of 15
(page number not for citation purposes)
study showed that administration of KetoCal®  under
restricted conditions was more effective in elevating circu-
lating ketone bodies than was administration under unre-
stricted conditions. This is important since mild ketosis,
under conditions of reduced glucose availability, is essen-
tial for enhancing the bioenergetic potential of normal
brain cells [5,17,18]. Additionally, ketone bodies may
directly protect normal neurons and glia from damage
associated with aggressive tumor growth through a variety
of neuroprotective mechanisms [59-64]. In contrast to
most conventional brain tumor therapies, which indis-
criminately target both normal cells and tumor cells, CR
and particularly restricted ketogenic diets such as KetoCal®
are the only known therapies that can target brain tumor
cells while enhancing the health and vitality of normal
brain cells [5,29]. In this regard, the calorically restricted
ketogenic diet for brain cancer management stands apart
from all conventional therapeutic approaches.
Previous studies indicate that many tumors including
brain tumors are largely unable to metabolize ketone bod-
ies for energy due to various deficiencies in one or both of
the key mitochondrial enzymes, β-OHBDH and SCOT
[19,21,65-68]. Our gene expression results in the mouse
CT-2A and the human U87 brain tumors are consistent
with these previous findings in other tumors and also sup-
port the mitochondrial defect theory of cancer
[5,23,24,69]. The deficiencies in these enzymes, however,
are important for tumor management only under calori-
cally restricted conditions when glucose levels are reduced
and when cells would require ketone bodies for energy.
This is most evident from the analysis of tumor growth in
the unrestricted KetoCal® groups where growth was rapid
despite mild ketosis. This is attributed to the maintenance
of high glucose levels, which the tumor cells will use for
energy in preference to ketone bodies due to their depend-
ency on glycolysis. However, when glucose becomes lim-
ited, as occurs under CR, the SCOT and β-OHBDH
deficiencies would prevent tumor cells from using ketones
Influence of diet on plasma glucose and β-OHB levels in B6 mice bearing the CT-2A astrocytoma (A and C), or in SCID mice  bearing the human U87 glioma (B and D) Figure 4
Influence of diet on plasma glucose and β-OHB levels in B6 mice bearing the CT-2A astrocytoma (A and C), or in SCID mice 
bearing the human U87 glioma (B and D). Values are expressed as mean ± SEM (n = 12–14 mice per group) and the asterisks 
indicate that the values differ from the control SD-UR group at the at the P < 0.01 level.Nutrition & Metabolism 2007, 4:5 http://www.nutritionandmetabolism.com/content/4/1/5
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Influence of diet on vascularity in the CT-2A (A and B) and the U87 (C) brain tumors grown orthotopically in B6 or SCID mice,  respectively Figure 5
Influence of diet on vascularity in the CT-2A (A and B) and the U87 (C) brain tumors grown orthotopically in B6 or SCID mice, 
respectively. Vessels were stained with the Factor VIII antibody and each stained section was representative of the entire 
tumor. For quantitative analysis of vessels in the CT-2A tumor, microvessel density was expressed as the number of vessels/
200 × high power field (hpf). The values are expressed as the mean of three independent samples with error bars representing 
SEM. The asterisks indicate that the number of vessels/hpf was significantly less in the KC-R group than in the SD-UR group at 
P < 0.05. The scale bar represents 250 μm.Nutrition & Metabolism 2007, 4:5 http://www.nutritionandmetabolism.com/content/4/1/5
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Expression of β-OHBDH and SCOT in B6 and SCID mouse brains and in CT-2A and U87 brain tumors Figure 6
Expression of β-OHBDH and SCOT in B6 and SCID mouse brains and in CT-2A and U87 brain tumors. (A) RT-PCR was used 
to detect mRNA levels of β-OHBDH, SCOT, and β-actin as described in methods. Expression was evaluated in normal appear-
ing B6 brain tissue (B6-B) contralateral to the CT-2A tumor, and in normal appearing SCID brain tissue (SCID-B) contralateral 
to the U87 tumor. (B) The ratio (relative intensity) of β-OHBDH and SCOT expression to β-actin expression. The values are 
expressed as the mean of three-four independent samples with error bars representing SEM. The asterisks indicate that the 
ratio was significantly less in the tumor tissue (solid bars) than in the normal brain tissue (open bars) at P < 0.01.Nutrition & Metabolism 2007, 4:5 http://www.nutritionandmetabolism.com/content/4/1/5
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as an alternative fuel thus metabolically isolating the
tumor cells from the normal cells. We suggest that the
genes for these enzymes could be useful markers for
screening brain tumors and other tumor types that may be
responsive to therapy using restricted KetoCal® or other
restricted ketogenic diets. Further studies will be necessary
to test this interesting possibility.
Long-term management of malignant brain cancer has
been difficult in both children and adults. This has been
due in large part to the unique anatomical and metabolic
environment of the brain that prevents the large-scale
resection of tumor tissue and impedes the delivery of
chemotherapeutic drugs. Further, significant neurological
abnormalities are often observed in long-term brain
tumor survivors [70-72]. In light of the differences in
energy metabolism between normal brain cells and brain
tumor cells, we recently proposed an alternative approach
to brain cancer management based on principles of evolu-
tionary biology and metabolic control theory [5]. Specifi-
cally, the genomic and metabolic flexibility of normal
cells, which evolved to survive under physiological
extremes, can be used to target indirectly the genetically
defective and less fit tumor cells. The results of this study
using restricted KetoCal® as a therapy for experimental
brain cancer provide direct support for this alternative
approach to brain cancer management. It should be recog-
nized that this alternative therapeutic approach may not
be restricted only to brain cancer, but could also be effec-
tive for any cancer types containing genetically compro-
mised and metabolically challenged tumor cells.
Moreover, KetoCal® will be more effective in managing
brain tumors in humans than in managing brain tumors
in mice since prolonged caloric restriction can be toler-
ated better in humans than in mice due to intrinsic differ-
ences in basal metabolic rate [30].
Although Nebeling and co-workers were successful in
managing childhood astrocytoma with a medium-chain
triglyceride ketogenic diet [29,73], this KD formulation
can be difficult to implement, is not standardized, and can
produce some adverse effects as previously observed in
children taking the diet for epilepsy management [32-34].
It is noteworthy that the children treated in the Nebeling
study also expressed reduced blood glucose levels [29].
When administered in restricted amounts, KetoCal® may
have greater therapeutic efficacy with fewer side effects
than medium-chain triglyceride or lard-based KDs. Addi-
tionally, KetoCal® would eliminate or reduce the need for
antiepileptic drugs for brain tumor patients since KetoCal®
was designed originally to manage refractory epileptic sei-
zures. Adjuvant steroidal medications, which are often
prescribed to brain tumor patients and which can produce
severe adverse effects, might also be reduced under the
restricted KetoCal® diet since glucocorticoid levels increase
naturally under calorically restricted conditions [74-76].
Ketogenic diets and calorically restricted diets can also
antagonize cancer cachexia [9,11,77]. These observations,
considered together with the anti-angiogenic effects of the
diet, suggest that the restricted KetoCal® diet can manage
brain tumors through multiple integrated systems.
Guidelines for the implementation of KetoCal® and other
calorie restricted KDs in younger and older patients have
been described previously [5,29,34,73]. KetoCal® could be
administered to patients with brain tumors at medical
centers or clinics currently using the ketogenic diet for
managing epilepsy. Based on our findings in mice and
those of Nebeling and co-workers in humans, initiation of
randomized clinical trials are warranted to determine
whether KetoCal® is effective for the long-term manage-
ment of malignant brain cancer and possibly other glyco-
lysis dependent cancers [78]. This is especially pertinent to
patients with glioblastoma multiforme, an aggressive
brain tumor type for which few effective therapeutic
options are available. While KetoCal® was formulated for
managing childhood seizures, it is likely that new KD for-
mulations can be designed with nutritional and caloric
compositions more appropriate for managing brain
tumors [5,78]. This could also involve the use of low gly-
cemic diets, which are effective in maintaining low circu-
lating glucose levels and are easier to implement than
some ketogenic diets [79,80]. Additionally, the diets
could be combined with specific drugs to further enhance
therapeutic efficacy. As a cautionary note, the calorically
restricted KD would not be recommended for those few
individuals with fasting intolerance due to defects, either
inherited or drug-induced, in carnitine or fatty acid
metabolism [49]. Our results in mouse and human brain
tumor models suggest that the restricted KetoCal® diet will
be an effective alternative therapy for managing malig-
nant brain cancer in humans and should be considered as
either a first line or adjuvant therapeutic option.
Conclusion
The results indicate that KetoCal®  administered in
restricted amounts has anti-tumor and anti-angiogenic
effects in experimental mouse and human brain tumors.
Furthermore, genes for ketone body metabolism will be
useful for screening brain tumors that could be targeted
with KetoCal® or other calorically restricted high fat low
carbohydrate diets. This preclinical study in mice indi-
cates that the restricted KetoCal® diet should be an effec-
tive alternative therapeutic option for managing
malignant brain cancer in humans.
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